Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE.

Objective To evaluate the safety and efficacy of CD19 chimeric antigen receptor (CAR) T cell therapy in a patient with refractory lupus nephritis who experienced severe disease flare during ...

Background SLE is associated with significant morbidity, especially in the case of renal involvement. Mitochondrial dysfunction plays a significant role in SLE and may be assessed by measuring ...

Objective This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; ...

Objective Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological diagnosis that can be associated with SLE. The clinical presentation, risk factors and outcomes of PRES in ...

Objective The question of sustained remission in SLE has been highlighted recently following data published on the use of chimeric antigen receptor-T cell therapy in SLE. With the review, we wanted to ...

Objective To characterise the safety and efficacy of anifrolumab in active lupus nephritis (LN) through year 2 of the phase II randomised, double-blind Treatment of Uncontrolled Lupus via the ...

Geraldino-Pardillaet al.1 recently published an interesting article analysing one of the most important aspects of systemic lupus erythematosus (SLE): the risk of cardiovascular disease, a leading ...

LP-198 Clinical response by subgroups in patients with systemic lupus erythematosus (SLE) receiving standard of care treatment plus placebo (SOC+PBO): a post hoc analysis from clinical trial data (6 ...

22 Historical aspects of B-cell depletion in SLE (8 October, 2025) ...

Background Abnormalities of type I interferon signaling and production can initiate lupus development. Disturbances of nucleic acid-sensing molecules triggered autoreactivity in lupus mouse models.